$35.38
0.86% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US00847X1046
Symbol
AGIO

Agios Pharmaceuticals, Inc. Stock price

$35.38
-3.85 9.81% 1M
+2.57 7.83% 6M
+2.52 7.67% YTD
-9.36 20.92% 1Y
+7.23 25.68% 3Y
-4.92 12.21% 5Y
-60.77 63.20% 10Y
+4.10 13.11% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.30 0.86%
ISIN
US00847X1046
Symbol
AGIO
Industry

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.1b
Net debt
positive
Cash
$938.9m
Shares outstanding
58.0m
Valuation (TTM | estimate)
P/E
3.1 | negative
P/S
49.9 | 47.0
EV/Sales
26.9 | 25.3
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
92.7%
Return on Equity
43.7%
ROCE
44.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$40.9m | $43.4m
EBITDA
$632.9m | $-487.7m
EBIT
$627.6m | $-497.2m
Net Income
$650.1m | $-428.4m
Free Cash Flow
$-409.0m
Growth (TTM | estimate)
Revenue
30.6% | 18.9%
EBITDA
258.6% | -16.1%
EBIT
254.9% | -16.8%
Net Income
278.1% | -163.6%
Free Cash Flow
-33.0%
Margin (TTM | estimate)
Gross
88.2%
EBITDA
1,548.3% | -1,123.4%
EBIT
1,535.4%
Net
1,590.4% | -986.9%
Free Cash Flow
-1,000.7%
More
EPS
$11.2
FCF per Share
$-7.0
Short interest
7.3%
Employees
487
Rev per Employee
$70.0k
Show more

Is Agios Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Agios Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

11x Buy
73%
4x Hold
27%

Analyst Opinions

15 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Agios Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
41 41
31% 31%
100%
- Direct Costs 4.83 4.83
45% 45%
12%
36 36
29% 29%
88%
- Selling and Administrative Expenses 178 178
39% 39%
435%
- Research and Development Expense 320 320
5% 5%
783%
633 633
259% 259%
1,548%
- Depreciation and Amortization 5.25 5.25
12% 12%
13%
EBIT (Operating Income) EBIT 628 628
255% 255%
1,535%
Net Profit 650 650
278% 278%
1,590%

In millions USD.

Don't miss a Thing! We will send you all news about Agios Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agios Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia
Positive
The Motley Fool
11 days ago
Agios Pharmaceuticals (AGIO -6.15%), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable revenue beat: This quarter showcased clear progress on sales for its lead product PYRUKYND, with GAAP net product revenue of $12.5 million, yet also highlighted the company's increasing cost base as it ...
Neutral
Seeking Alpha
12 days ago
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Morgan Sanford - Vice President, Investor Relations Conference Call Participants Andrew Scott Beren...
More Agios Pharmaceuticals, Inc. News

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Goff
Employees 487
Founded 2007
Website www.agios.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today